Trademark: 86865972
Word
HEALTH NUCLEUS
Status
Dead
Status Code
603
Status Date
Thursday, May 2, 2019
Serial Number
86865972
Mark Type
3000
Filing Date
Tuesday, January 5, 2016
Abandoned Date
Thursday, May 2, 2019

Trademark Owner History

Classifications
42 scientific research services in the field of genomics and advanced clinical imaging to be used for personalized health; research and development in the field of genome sequencing and genome analysis; providing scientific analysis of aggregated results comprised primarily of genomic and microbiome sequencing, genomic and microbiome analysis, genetic testing and screening for research purposes, metabolomics data, phenotyping data, molecular analytics, patient scientific and medical information, genealogical information, health risk assessment, and preparing related information reports therefor; providing scientific analysis of aggregated results comprised primarily of genomic and microbiome sequencing, genomic and microbiome analysis, genetic testing and screening for research purposes, metabolomics data, phenotyping data, molecular analytics, patient scientific and medical information, genealogical information, health risk assessment through advanced clinical imaging, namely, ultrasound imaging, magnetic resonance imaging (MRI), X-ray, radiography, computed tomography (CT), fluoroscopy, positron emission tomography, mammaography, and echocardiogram services, and preparing related information reports therefor; providing online searchable databases in the fields of genomic and microbiome sequencing, genomic and microbiome analysis, genetic testing and screening for research purposes, metabolomics data, phenotyping, molecular analytics, patient scientific and medical information, genealogical information, advanced clinical imaging, health risk assessment for scientific research purposes; application service provider (ASP) featuring software for use in data management, data storage, data analysis, report generation, all in the fields of genomic and microbiome sequencing, genomic and microbiome analysis, genetic testing and screening for research purposes, and health risk assessment; scientific research in the fields of genomics, genetics, genetic testing, genetic screening, genotyping, phenotyping, molecular analytics, health risk assessment, and genealogical information; scientific research in the fields of genomics, genetics, genetic testing, genetic screening, genotyping, phenotyping, molecular analytics, health risk assessment through advanced clinical imaging, namely, ultrasound imaging, magnetic resonance imaging (MRI), X-ray, radiography, computed tomography (CT), fluoroscopy, positron emission tomography, mammaography, and echocardiogram services, and genealogical information; medical research; scientific investigations for medical purposes; medical and scientific research in the field of medical imaging; compiling data for research purposes in the field of medical science and medical consultancy; medical and scientific research in the field of genome sequence analysis and genome sequence reporting for research purposes, microbiome sequencing, metabolome analysis, advanced clinical imaging, laboratory tests, health risk assessment, medical imaging and DNA screening; research and development in the field of genome sequence analysis and genome sequence reporting, microbiome sequencing, metabolome analysis, advanced clinical imaging, laboratory tests, health risk assessment, medical imaging and DNA screening; scientific research for medical purposes in the field of genome sequence analysis and genome sequence reporting, microbiome sequencing, metabolome analysis, advanced clinical imaging, laboratory tests, health risk assessment, medical imaging and DNA screening; genetic testing of humans for scientific research purposes; all for scientific research purposes
44 genetic testing of humans for medical diagnostic purposes; consulting services in the fields of diagnostic medical testing; DNA screening for medical purposes; genetic counseling; medical assistance consultancy provided by doctors and other specialized medical personnel; medical assistance consultancy provided by genomics and genetics experts; medical assistance services in the nature of genetic and medical information provided to medical professionals from remote locations via the internet and global computer networks through the use of archived genome sequence information, medical images, diagnostic test results, and a data storage and retrieval system; medical genetic testing consultations provided via phone, online chat or videoconferencing; medical diagnostic testing, monitoring and reporting services; medical imaging services; medical information; medical screening; medical testing for diagnostic purposes; medical testing of blood, saliva, stool; multi-disciplinary, integrative, genetic consultations for medical treatment purposes; providing a web site featuring genetic and medical information; providing an internet website for medical professionals and medical patients featuring medical information from remote locations via devices that feed information to the website that is processed, exchanged and accessed in real-time by users; providing an internet website for medical professionals and medical patients featuring medical information from remote locations via electronic patient monitoring devices that feed information to the web site that can be accessed in real-time by medical professionals for purposes of monitoring and diagnosing medical conditions; providing medical information; providing medical information, consultancy and advisory services; providing medical profiles and medical record analysis and assessments via a website that are designed to provide custom tailored outputs about recommended resources and treatments associated with a defined set of symptoms, concerns, genome sequencing analysis, microbiome sequencing analysis, metabolome analysis, advanced clinical imaging, laboratory tests, and medical imaging and DNA screening; providing medical testing and medical consultations to individuals and their physicians to help them make health, wellness and nutritional changes in their daily living to improve health; providing on-line medical record analysis services designed to provide patients with custom tailored information about the range of possible diagnoses and therapies associated with a defined set of symptoms based on genome sequencing analysis, microbiome sequencing analysis, metabolome analysis, advanced clinical imaging, laboratory tests, and medical imaging and DNA screening; provision of health care and medical services by health care professionals via the internet or telecommunication networks; remote monitoring of data indicative of the health or condition of an individual or group of individuals for medical diagnosis and treatment purposes; health assessment services, namely, providing assessment of risk of disease and providing health monitoring of individuals all through use of genome sequencing analysis and reporting, microbiome sequencing analysis, metabolome analysis, advanced clinical imaging, laboratory tests, and medical imaging and DNA screening; all for medical treatment and diagnostic purposes
Color is not claimed as a feature of the mark.
"HEALTH"
The mark consists of the words "HEALTH NUCLEUS" in stylized font with a solid circle in the center of the "C".

Trademark Events
May 6, 2019
Abandonment Notice Mailed - After Ex Parte Appeal
May 2, 2019
Abandonment - After Ex Parte Appeal
May 2, 2019
Exparte Appeal Terminated
May 2, 2019
Exparte Appeal Dismissed
Apr 11, 2019
Notification Of Examiners Statement E-Mailed
Apr 11, 2019
Examiners Statement E-Mailed
Apr 11, 2019
Examiners Statement - Completed
Mar 4, 2019
Assigned To Examiner
Feb 13, 2019
Jurisdiction Restored To Examining Attorney
Jun 12, 2018
Ex Parte Appeal-Instituted
Jun 12, 2018
Exparte Appeal Received At Ttab
Dec 13, 2017
Notification Of Final Refusal Emailed
Dec 13, 2017
Final Refusal E-Mailed
Dec 13, 2017
Final Refusal Written
Nov 21, 2017
Teas/Email Correspondence Entered
Nov 20, 2017
Correspondence Received In Law Office
Nov 21, 2017
Teas/Email Correspondence Entered
Nov 21, 2017
Correspondence Received In Law Office
Nov 20, 2017
Teas Response To Office Action Received
May 19, 2017
Notification Of Non-Final Action E-Mailed
May 19, 2017
Non-Final Action E-Mailed
May 19, 2017
Non-Final Action Written
May 9, 2017
Lie Checked Susp - To Atty For Action
May 9, 2017
Assigned To Lie
Nov 1, 2016
Notification Of Letter Of Suspension E-Mailed
Nov 1, 2016
Letter Of Suspension E-Mailed
Nov 1, 2016
Suspension Letter Written
Oct 19, 2016
Teas/Email Correspondence Entered
Oct 19, 2016
Correspondence Received In Law Office
Oct 19, 2016
Teas Response To Office Action Received
Apr 19, 2016
Notification Of Non-Final Action E-Mailed
Apr 19, 2016
Non-Final Action E-Mailed
Apr 19, 2016
Non-Final Action Written
Apr 12, 2016
Assigned To Examiner
Jan 14, 2016
Notice Of Design Search Code E-Mailed
Jan 13, 2016
New Application Office Supplied Data Entered In Tram
Jan 8, 2016
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24